AMENDMENT #1 Compound Pharmaceuticals for Dept of Pharmacy, Carl R. Darnall Army Medical Center, Fort Hood, Tx.

Solicitation / RFP / RFQ

This solicitation, W81K0026QA064, is for the procurement of compound pharmaceuticals. The government is seeking offers for these products to meet specific requirements.

• The solicitation details specific compound pharmaceuticals, including Succinylcholine Chloride, Oxytocin, L.E.T. (Lidocaine, Epinephrine, Tetracaine), and Phenylephrine HCl.

• Quantities and specific formulations (e.g., concentration, volume, base solution) are provided for each item.

• Minimum shelf life requirements (e.g., 45 days at room temperature) and storage conditions are specified.

• Offerors must be able to provide the ENTIRETY of the requested compound pharmaceuticals; partial offers will be considered ineligible for award.

• Products must be compounded using only FDA-approved drugs, containers, and diluents.

• Compliance with Trade Agreements Act (TAA) is required for ingredients.

• Delivery must be within +/- 10% of USP standards.

• Compliance with the Compounding Quality Act Title I of the Drug Quality and Security Act of 2013 is required.

• Compliance with Current Good Manufacturing Practices (cGMP) (section 503b) is mandatory.

• Products must be labeled according to NPSG.03.04.01 for Joint Commission standards.

• QI/QA certification is required for every batch, regardless of size.

• 24/7 customer service is required.

• Compliance with DEA Licensing requirements for manufacturing and distribution of controlled substances is necessary.

• Specific elements of compliance for the Carl R. Darnall Army Medical Center (CRDAMC) are outlined, noting that patient-specific prescriptions do not meet bulk compound requirements.

• The period of performance spans multiple years, with specific delivery periods outlined for each item, generally from October 1st to September 30th of subsequent years, starting in 2026 and extending to 2030.

• Pricing arrangement is Firm Fixed Price.

• The solicitation issue date is January 29, 2026.

• The offer due date is February 12, 2026, at 10:00 AM local time.

• Award will be made using a Lowest Price Technically Acceptable (LPTA) source selection process.

• Quotes must be submitted electronically via email to sheryl.j.egans.civ@health.mil.

• Questions regarding the solicitation are due by February 3, 2026, 8 AM CST.

• Responses to questions will be published on SAM.gov by February 5, 2026.

• Quotes must be clear, concise, and include sufficient detail for effective evaluation.

• Offerors must provide documented proof of certification/accreditations (FDA or PCAB), USP Chapter compliance, and a Quality Control system.

• Technical acceptability is a mandatory requirement for award. Documentation must clearly meet minimum requirements.

• Pricing must be submitted for all compound pharmaceuticals, including unit and total extended prices.

• Offerors agree to hold prices for ninety (90) days from the quote submission.

• The acquisition is set aside for Small Business.

• NAICS Code: 325412, Size Standard: 1300.

• The document includes numerous FAR and DFARS clauses incorporated by reference and in full text, covering various aspects such as contract terms, representations and certifications, payment instructions, and evaluation criteria.